Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Atara Biotherapeutics (ATRA) Leases (2022 - 2025)

Atara Biotherapeutics' Leases history spans 4 years, with the latest figure at $7.1 million for Q4 2025.

  • For Q4 2025, Leases fell 82.25% year-over-year to $7.1 million; the TTM value through Dec 2025 reached $7.1 million, down 82.25%, while the annual FY2025 figure was $7.1 million, 82.25% down from the prior year.
  • Leases reached $7.1 million in Q4 2025 per ATRA's latest filing, down from $10.7 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $73.6 million in Q2 2022 to a low of $7.1 million in Q4 2025.
  • Average Leases over 4 years is $46.2 million, with a median of $51.4 million recorded in 2024.
  • Peak YoY movement for Leases: surged 244.07% in 2023, then plummeted 82.25% in 2025.
  • A 4-year view of Leases shows it stood at $68.0 million in 2022, then dropped by 19.24% to $54.9 million in 2023, then decreased by 27.54% to $39.8 million in 2024, then tumbled by 82.25% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Leases are $7.1 million (Q4 2025), $10.7 million (Q3 2025), and $11.0 million (Q2 2025).